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OBJECTIVES: Despite its rising popularity, reports on the use of preoperative imatinib mesylate (IM) in patients
with advanced gastrointestinal stromal tumor (GIST) are limited. This study aims to explore the clinical efficacy
of preoperative IM in patients with primarily unresectable or metastatic/recurrent GIST.
METHODS: Between September 2009 and February 2014, patients with primarily unresectable or metastatic/
recurrent GIST treated by a single medical team were recruited and considered for preoperative IM therapy. Re-
examination was conducted regularly and abdominal enhanced CT data, blood biochemistry and responses to
IM were recorded.
RESULTS: A total of 18 patients were enrolled, including 13 with a primary tumor (7 stomach, 3 small bowel, 2
rectal and 1 pelvic tumor) and 5 with recurrent or metastatic GIST (2 with liver metastasis, 2 with anastomotic
recurrence and 1 with pelvic GIST). The median follow-up time was 9.5 months (range of 3-63). The median
tumor sizes before and after initiation of IM treatment were 9.1 cm and 6.0 cm (p=0.003) based on the CT
findings, respectively. All patients showed a decrease in tumor burden and the median tumor size reduction
was 35%. Sixteen of the 18 patients showed a partial response to IM and two possessed stable disease. Nine of
the 18 patients (50%) underwent surgical resection of primary or metastatic/recurrent tumors, with a median of
7 months of IM therapy. One case each of multivisceral resection and tumor recurrence were noted.
CONCLUSIONS: IM as a preoperative therapy is feasible and safe for unresectable or metastatic/recurrent GIST
that can effectively decrease tumor size, facilitating resection.
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& INTRODUCTION
Currently, the standard treatment for gastrointestinal
stromal tumor (GIST) is radical surgery aimed at obtaining
negativemicroscopic margins (1). However, GIST patients are
at risk of recurrence and approximately 40-50% of those who
undergo radical resections will develop recurrence or
metastasis (2). In some patients, the lesion cannot be
completely removed, which has been shown to be partially
due to specific anatomic locations (esophagogastric junction,
duodenum, or low rectum) and huge tumor diameters (3-4).
Treatment of these patients can only be completed after
extensive procedures are performed that are associated with
increased risks for postoperative complications andmortality.
As understanding of the molecular pathogenesis of GIST has
increased, imatinib mesylate (IM) (GlivecH/GleevecH, Novartis
Pharma AG, Basel, Switzerland) has emerged as a targeted
therapy that represents the first effective, globally approved,
nonsurgical treatment for GIST. Previously published research
has suggested that IM considerably improves the prognosis of
patients with locally advanced and metastatic GIST (5-6). A
large, non-blinded trial of patients with unresectable or
metastatic GIST treated with IM demonstrated a median time
to progression of 24 months and amedian overall survival time
of 57months (7). In addition, recent reports have suggested that
preoperative IM use can increase the resectability rate and
reduce procedure-related mortality, thereby improving the
survival of GIST patients (8-9). However, few rigorous studies
on preoperative IM therapy in GIST patients exist to date, the
majority of which are retrospective.
Therefore, the purpose of present study was to prospec-
tively analyze the clinical efficacy of preoperative IM
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therapy administered at a single institution in Chinese
patients with unresectable or metastatic/recurrent GIST
with the goal of standardizing the preoperative use of IM in
the future.
& MATERIALS AND METHODS
Patient selection
All included patients were treated by the same medical
team at a single institution (Department of Gastrointestinal
Surgery, West China Hospital, Sichuan University, China)
between September 2009 and February 2014.
The inclusion criteria were as follows: A patients with
primarily unresectable or metastatic/recurrent GIST (unre-
sectable tumors were defined as being huge in size or
having already infiltrated the adjacent tissues and organs
with unclear boundaries, according to radiological find-
ings); B GIST that was confirmed by immunohistochemical
staining and/or KIT and platelet-derived growth factor
receptor A (PDGFRA) mutation detection (samples were
acquired by endoscopic ultrasound-guided fine-needle
aspiration biopsy or needle biopsy guided by abdominal
CT (10); and C patients with no history of taking IM who
were over eighteen of age. The exclusion criteria were as
follows: A patients with major contraindications to IM
therapy (such as allergies); B pregnant or lactating women;
and C absence of additional concurrent malignant tumors.
IM treatment and surgery
All of the patients signed informed consent before treat-
ment. The subjects generally received systemic therapy at a
dosage of 400 mg/d. Upon disease progression, the dosage
was to 600 mg or higher per day or surgical treatment was
indicated. Clinical efficacy and drug toxicity were assessed
biweekly during the first month of treatment and then each
month the next three months. Thereafter, these parameters
were assessed every three months through outpatient follow-
up office visits or occasionally via email. Patient responses
were evaluated according to the Choi criteria (11).
All surgical procedures were conducted by the same
medical team at the West China Hospital. When disease
progression was determined or surgery was deemed
feasible by surgeons (namely, when the best response was
considered to be obtained in the absence of further
improvement as shown by 2 successive CT scans), surgical
treatment was performed. The primary surgical aims were
to maintain as many residual organ functions as possible
and to achieve R0 resection as frequently as possible. To
achieve a radical cure, additional debulking surgery was
performed in some cases, mainly if the tumor had infiltrated
adjacent tissues and organs. Frozen slices of the incisal
margin and tumor were routinely collected during surgery.
Patient follow-up
All included patients were mainly followed up on an
outpatient basis or through email. The clinical data
presented here are up to date through May 2014 and
include a median follow-up time of 9.5 months (range of 3-
63) from the onset of medication administration. The follow-
up assessments included abdominal enhanced CT, whole
blood count and classification, evaluations of liver and
kidney functions, clinical examination and medication
compliance assessment.
Data and statistical analysis
The continuous variables are described using the median
and range. The differences between the tumor sizes before
and after administration of IM treatment were compared
using an independent samples t-test. Because of the limited
sample size and short-term follow up, no patient survival
analysis was attempted. Statistical analyses were performed
using SPSS 17.0 software package (SPSS, Chicago, IL, USA).
Differences were considered statistically significant when
the p-value was less than 0.05.
& RESULTS
Demographic and Clinical Characteristics
As of February 2014, a consecutive series of 18 patients
with unresectable or metastatic/recurrent GIST treated by
the same medical team at a single institution were enrolled
in the present study. The main clinical characteristics of
these 18 patients are presented in Tables 1 and 2. Thirteen of
the 18 cases included primary tumors (stomach in 7, small
bowel in 3, rectum in 2 and pelvis in one case), and 5
possessed recurrent or metastatic GIST (liver metastasis in 2,
anastomotic recurrences in 2 and pelvic cavity GIST in one
case). In total, 6 patients presented with hepatic metastasis.
One patient (no. 4) died due to disease progression at 12
months after initiation of IM treatment and 1 patient (no. 3)
experienced disease recurrence during follow-up. The
median age of the patients at diagnosis was 48 years (range
Table 1 - Main clinical characteristic of patients with primary GIST.
Patient
no. Sex
Age
(years)
Primary tumor
site
Metastatic
location
Operative
treatment
Preoperative
medication duration
(months)
Medication duration for
nonsurgical patients
(months)
Mutation
status
1 M 59 Stomach None Yes 15 - Exon 11
2 F 68 Stomach None Yes 2 - Exon 11
3 M 40 Small bowel None Yes 9 - Exon 11
4 M 46 Stomach Liver No - 12 Exon 9
5 M 40 Pelvis None No - 57 Exon 13
6 M 74 Stomach Liver No - 6 Exon 11
7 M 40 Small bowel Liver No - 6 Unknown
8 M 70 Stomach Liver No - 21 Exon 11
9 F 51 Rectum None Yes 4.5 - Exon 11
10 M 87 Stomach None No - 7 Unknown
11 M 77 Stomach None No - 7 Unknown
12 M 55 Small bowel None Yes 9 - Exon 11
13 M 46 Rectum None Yes 7 - Exon 11
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of 30-87). The male to female ratio was 1553. Fourteen genetic
mutation results were available (10 mutations were in exon
11, 3 were in exon 9 and 1 was in exon 13) and the genetic
mutations in the four remaining patients were unavailable
(they all refused to submit to genetic mutation assessments,
mainly for economic reasons). Considering the paucity of
data available on genetic mutations, no efficacy evaluation
associated with genetic mutations was attempted.
Preoperative IM Treatment
A total of 9 patients (50.0%) underwent surgery after the
IM treatment. The median durations of preoperative
medication use in the patients that did and did not receive
surgical intervention were 7 months (range of 1-15) and 8
months (range of 6-57), respectively. Seventeen patients
received a standard dosage of 400 mg daily, with the
exception of patient no. 18, who was administered a dosage
of 600 mg/d (because tumor recurrence occurred at the
dosage of 400 mg/d). The IM dose was also raised to
600 mg/d for patient no. 4 due to a decrease and
subsequent increase in tumor size. No other patients
discontinued or reduced their IM dosages. No treatment-
related serious adverse effects were documented during the
follow-up period. The median tumor size before and after
initiation of IM treatment (considering the best response
obtained or that reported at the end of follow-up) were
9.1 cm (range of 3.0-16.8) and 6.0 cm (range of 2.5-11.1)
(p=0.003) based on the CT findings, respectively. The
median tumor size reduction after IM therapy was 35%
(range of 1-62%). However, the sizes of the hepatic
metastases decreased in six cases, although not significantly
(p=0.614), with a median reduction of 20.1%. No complete
responses were observed; however, 16 patients (88.9%)
showed a partial response and two (11.1%) possessed stable
disease according to the Choi criteria. One patient with a
partial response experienced disease progression and
another suffered from postoperative tumor recurrence.
Surgery Information
Some patients refused surgery due to a partial radiological
response, fear of surgery or other reasons. All decisions to
proceed with surgery were made collectively by three senior
surgeons from ourmedical team. In total, 9 patients eventually
agreed to receive surgical treatment after the preoperative IM
treatment. Two underwent bowel resection (nos. 3 and 12);
however, patient no. 3 had a positive margin due to severe
tumor invasion. One patient underwent radical distal gas-
trectomy (no. 2), one received rectal tumor resection and
sigmoid colostomy (no. 9), one underwent recurrent tumor
resection (no. 14), one received right liver metastasis resection
and radiofrequency ablation (no. 16) and one received multi-
organ resection and radical proximal gastrectomy with
splenectomy (no. 1, as shown in Figures 1A, 1B and 1C).
Two additional patients underwent pelvic tumor resection
and another 2 received rectal tumor resection. No periopera-
tive deaths or blood transfusions occurred. All operated
patients received IM treatment after recovering their gastro-
intestinal functions and drug tolerance. The median duration
of adjuvant therapy with IM was 3 months (range of 2-13)
until the deadline for follow-up of May 2014.
Evaluation of Tumor Imaging
All patients underwent abdominal enhanced CT exam-
ination before IM treatment and during subsequent hospital
visits. The CT results characterized the metastases and
tumor sizes and tumor density was shown to be reduced in
most patients, indicating relatively well-defined tumors
(Figures 2 and 3). However, two patients experienced very
subtle changes bordering on slight increases in tumor size
after the IM treatment (nos. 2 and 17). A partial response
was noted in the remaining 16 patients, which was defined
as a complete or mainly central liquefactive necrosis of the
lesion (as depicted in Figure 4). A lesion with a huge mass
originating from the jejunum that nearly occupied the entire
abdominal cavity was observed in one case; however, the
tumor size was reduced by approximately one-third after 9
Table 2 - Main clinical characteristic of patients with recurrent/metastatic GIST.
Patient
no. Sex
Age
(years)
Previous
tumor site
Recurrent/metastatic
location
Operative
treatment
Preoperative
medication duration
(months)
Medication duration of
nonsurgical patients (months) Mutation status
14 M 45 Rectum Anastomosis No - 8 Unknown
15 M 30 Small bowel Anastomosis Yes 1 - Exon 11
16 M 42 Rectum Liver No - 35 Exon 11
17 M 39 Small bowel Liver Yes 9 - Exon 9
18 F 50 Small bowel Pelvis Yes 1 - Exon 9
Figure 1 - (Patient no. 1, ABC) The abdominal enhanced CT scan
(A) obtained at 3 months after initiation of IM therapy shows the
tumor abutting the spleen (indicated by the arrow). However,
after an additional 11 months of treatment, the CT findings (B)
indicate tumor shrinkage and clearer tumor boundaries. (C) The
operative photo shows that the patient underwent proximal
gastrectomy with splenectomy. (Patient no. 3, DEF) This CT scan
shows a huge tumor located in the abdominal cavity before
medical treatment (D). The mass of this lesion was reduced
significantly after 9 months of treatment (E). Unfortunately, this
patient experienced tumor recurrence at 14 months postopera-
tively and the CT scan (F) shows the location of the tumor in the
upper left abdomen, spanning an area of 5.3 centimeters by 4.9
centimeters.
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months of medication (Figures 1D and 1E). Still, this patient
experienced postoperative tumor recurrence at 14 months
(one month after interruption of IM therapy, Figure 1F).
& DISCUSSION
GIST is the most common mesenchymal tumor of the
digestive tract (6). This tumor is considered to originate from a
common precursor of the interstitial Cajal cells or its precursor
cells and are characterized by the presence of activating
mutations in KIT and platelet-derived growth factor receptor
(PDGFR) (12-13). GIST diagnoses have increased over the past
two decades, which is partially due to an increase in relevant
information available and improved reclassification guide-
lines (14). IM, whichwas originally designed as an inhibitor of
Bcr-Abl but was later also demonstrated to effectively inhibit
the tyrosine kinase activities of KIT and PDGFR, was shown
to markedly increase the recurrence-free and overall survival
rates of GIST patients, suggesting that this therapy is effective
as a standard of care in the adjuvant treatment of these
patients (15).
Preoperative IM therapy for primary unresectable or
recurrent/metastatic GIST can shrink the tumor size, increase
the resectability rate and achieve a potentially better clinical
outcome (8,16). Fiore et al. have shown a median tumor size
reduction of 34% after preoperative medication administered
for a median duration of 9 months at a standard dose of 400
mg/d (17). These findings are consistent with those of the
present study, in which the median tumor size reduction was
35%. Of the tumors that were initially considered to be
unresectable, half eventually underwent surgical resection
and only one was observed with a positive incisal margin.
The use of surgery following IM treatment for patients with
advanced GIST remains controversial in this era of molecular
targeted therapy because such good therapeutic results were
obtained with IM. The vast majority of unresectable GIST is
due to extremely large tumor sizes or to excessive tumor
infiltration. Huge GIST is typically supplied by multi-source
arteries and it sometimes exhibit plexiform-like layers
attached to a meager envelope. Uncontrollable bleeding
may occur despite careful surgery.
The effects of IM on surgical intervention and outcome
after surgical resection in 37 patients with GIST were
previously investigated (18). The results showed that
approximately 89% of the patients underwent complete
resection. In the present study, 8 cases (88.9%) underwent
involved the complete removal of the tumor and achieve-
ment of a negative incisal margin after preoperative IM
treatment in accordance with the aforementioned previous
results. Enhanced abdominal CT is routinely used to
monitor the responses of GIST to IM (19). Changes in tumor
density, vessels and size as shown by CT scan may provide
information regarding the biological behaviors and effects
of the treatment to a certain extent. Evident changes in
tumor size and density were observed in our study and our
radiographic assessment showed that approximately 89% of
the patients had a partial response to IM, similar to previous
findings (20). It is possible that multivisceral resection may
occur in huge or locally advanced GIST. Therefore, the
NCCN guidelines state that for multivisceral resection huge,
poorly positioned or recurrent/metastatic GIST, preopera-
tive IM treatment may be beneficial (21). The separation and
removal of tumors to maintain increased organ function is
contradictory to the no-tumor principle. If patient quality of
Figure 2 - This CT scan obtained after medical treatment depicts
tumors located in the pelvic cavity (AB) and greater curvature
(CD) that significantly decreased in size and density (indicated by
arrows). Patient no. 4 (CD) died at 25 months after diagnosis due
to disease progression.
Figure 3 - Patient no. 13 underwent resection of rectal GIST eight
years prior (the thin arrow in A shows the anastomotic nail) and
the tumor was reduced by 61% after six months of IM treatment
at a dosage of 400 mg per day (indicated by thick arrows in AB).
CT scans showed a huge mass located in the pelvic cavity,
presenting as mixed cystic lesions (C). The tumor size decreased
after 4 months of IM treatment (D) and the patient received
surgical treatment at 4.5 months after initiation of IM treatment.
Figure 4 - Based on the CT images, the IM responses were rated
as partial. Patients no. 6 (AB) and no. 8 (CD) were first diagnosed
with combined liver metastases (black arrows in A and C) and
signs of liquefactive necrosis in the metastases and tumors were
both observed (white/black arrows in B and D) at two months
after initiation of IM treatment.
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life is not significantly influenced, multivisceral resection
should be completed within the tumor to achieve a negative
margin. In this study, one patient who received 9 months of
preoperative medication underwent multivisceral resection
(proximal gastrectomy with+ splenectomy). However,
although the mass was removed, R0 resection was not
achieved due to the huge tumor size.
The optimal duration of preoperative IM treatment is still
unknown and under debate. The European Society for
Medical Oncology (ESMO) guidelines recommend a period
of 6 to 12 months from the initiation of IM treatment until a
maximal response is noted in GIST patients and following
surgical intervention (22). It is well known that excessive
prolongation of preoperative medication may lead to second-
ary resistance and disease progression. Previous data
collected have shown a preoperative IM time range of 7.3 to
12.9 months as well as a significant reduction in tumor size
following IM treatment (17,20,23). We performed surgery
after a median time of 7 months (range of 1-15). Seven of the 9
operated patients experienced a reduction in tumor size and
achieved a maximal response, whereas the two remaining
patients showed almost no change after initiation of IM
treatment. One patient remained sensitive to IM after 57
months of treatment. Hence, the optimal duration of
preoperative therapy may vary from person to person. GIST
patients taking preoperative medications should continue
tyrosine kinase inhibitor (TKI) adjuvant therapy postopera-
tively because this practice has been proven to be beneficial
(24). Compared with 1 year of adjuvant IM treatment, three
years of this treatment have been shown to improve the
recurrence-free survival and overall survival rates of GIST
patients at a high risk of GIST recurrence (5). Among the 18
patients evaluated in our study, the median time of adjuvant
therapy was three months until the deadline for follow-up.
All of these patients continued with their use of this drug.
The present study has some limitations. Our series is a
small, non-randomized controlled trial, precluding any
definitive conclusions. Further studies should include large
sample sizes, rigorous sample assessments and multi-center
randomized controlled experiments. Our findings suggest that
preoperative IM therapy provides clinical benefits for Chinese
patients with unresectable or metastatic/recurrent GIST.
In conclusion, application of IM as a preoperative therapy
is feasible and safe for primarily unresectable or metastatic/
recurrent GISTs in Chinese patients and this treatment can
effectively decrease tumor size, facilitating successful tumor
resection.
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